SYT6

Summary

SYT6 (synaptotagmin 6, HGNC:18638) is a protein-coding gene on chromosome 1p13.2, encoding Synaptotagmin-6 (Q5T7P8). May be involved in Ca(2+)-dependent exocytosis of secretory vesicles through Ca(2+) and phospholipid binding to the C2 domain or may serve as Ca(2+) sensors in the process of vesicular trafficking and exocytosis.

The protein encoded by this gene belongs to the synaptotagmin family. Synaptotagmins share a common domain structure that includes a transmembrane domain and a cytoplasmic region composed of 2 C2 domains, and are involved in calcium-dependent exocytosis of synaptic vesicles. This protein has been shown to be a key component of the secretory machinery involved in acrosomal exocytosis. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 148281 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 66 total
• MANE Select transcript: NM_001253772

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18638
Approved symbol	SYT6
Name	synaptotagmin 6
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000134207
Ensembl biotype	protein_coding
OMIM	607718
Entrez	148281

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 nonsense_mediated_decay

ENST00000369547, ENST00000607941, ENST00000608203, ENST00000608879, ENST00000609117, ENST00000609577, ENST00000610096, ENST00000610121, ENST00000610222, ENST00000641643

RefSeq mRNA: 7 — MANE Select: NM_001253772 NM_001253772, NM_001270805, NM_001366223, NM_001366224, NM_001366225, NM_001366226, NM_205848

CCDS: CCDS871, CCDS91026, CCDS91027

Canonical transcript exons

ENST00000610222 — 8 exons

Exon	Start	End
ENSE00000913486	114103601	114103721
ENSE00001150890	114137495	114138053
ENSE00001402005	114093735	114093803
ENSE00001450305	114139615	114139963
ENSE00001450309	114089292	114092082
ENSE00001669170	114099094	114099265
ENSE00003557305	114153610	114153869
ENSE00003565406	114097727	114097877

Expression profiles

Bgee: expression breadth ubiquitous, 127 present calls, max score 95.50.

FANTOM5 (CAGE): breadth broad, TPM avg 0.8629 / max 35.5128, expressed in 231 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13936	0.6233	200
13939	0.0865	44
13937	0.0774	43
13938	0.0758	46

Top tissues by expression

229 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	95.50	gold quality
pancreatic ductal cell	CL:0002079	80.48	silver quality
ganglionic eminence	UBERON:0004023	79.46	gold quality
nucleus accumbens	UBERON:0001882	74.15	gold quality
hypothalamus	UBERON:0001898	73.95	gold quality
tibialis anterior	UBERON:0001385	72.41	silver quality
caudate nucleus	UBERON:0001873	72.04	gold quality
primary visual cortex	UBERON:0002436	70.68	gold quality
putamen	UBERON:0001874	70.57	gold quality
ileal mucosa	UBERON:0000331	70.02	gold quality
kidney epithelium	UBERON:0004819	69.35	gold quality
prefrontal cortex	UBERON:0000451	68.22	gold quality
body of pancreas	UBERON:0001150	67.57	gold quality
dorsal root ganglion	UBERON:0000044	67.45	gold quality
cerebellar vermis	UBERON:0004720	66.75	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	66.54	gold quality
occipital lobe	UBERON:0002021	66.32	gold quality
anterior cingulate cortex	UBERON:0009835	65.60	gold quality
spinal cord	UBERON:0002240	65.34	gold quality
Brodmann (1909) area 23	UBERON:0013554	64.67	silver quality
ventricular zone	UBERON:0003053	64.45	gold quality
neocortex	UBERON:0001950	64.41	gold quality
deltoid	UBERON:0001476	64.29	silver quality
cerebral cortex	UBERON:0000956	63.44	gold quality
forebrain	UBERON:0001890	63.28	gold quality
frontal cortex	UBERON:0001870	63.01	gold quality
amygdala	UBERON:0001876	62.94	gold quality
Ammon’s horn	UBERON:0001954	62.45	gold quality
middle temporal gyrus	UBERON:0002771	62.33	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	61.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

94 targeting SYT6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349

Literature-anchored findings (GeneRIF, showing 3)

• Acrosomal exocytosis is regulated through the PKC-mediated phosphorylation of conserved threonines in the polybasic regions of synaptotagmin VI. (PMID:16111671)
• SYT6 is hypermethylated in renal cell carcinoma. (PMID:18639284)
• synaptotagmin must be dephosphorylated at a specific window of time and phosphorylated synaptotagmin has an active role at early stages of the acrosomal exocytosis. (PMID:20551332)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	syt6b	ENSDARG00000031463
danio_rerio	syt6a	ENSDARG00000076730
mus_musculus	Syt6	ENSMUSG00000027849
rattus_norvegicus	Syt6	ENSRNOG00000019163

Paralogs (31): SYT7 (ENSG00000011347), SYT13 (ENSG00000019505), SYT1 (ENSG00000067715), RPH3A (ENSG00000089169), SYTL4 (ENSG00000102362), SYT17 (ENSG00000103528), SYT10 (ENSG00000110975), SYT5 (ENSG00000129990), SYT11 (ENSG00000132718), SYT4 (ENSG00000132872), SYTL2 (ENSG00000137501), SYT16 (ENSG00000139973), SYTL1 (ENSG00000142765), SYT14 (ENSG00000143469), SYT2 (ENSG00000143858), SYTL5 (ENSG00000147041), SYT8 (ENSG00000149043), DOC2A (ENSG00000149927), SYTL3 (ENSG00000164674), TC2N (ENSG00000165929), SYT9 (ENSG00000170743), SYT12 (ENSG00000173227), RPH3AL (ENSG00000181031), C2CD4C (ENSG00000183186), C2CD4A (ENSG00000198535), SYT15 (ENSG00000204176), C2CD4B (ENSG00000205502), SYT3 (ENSG00000213023), C2CD4D (ENSG00000225556), DOC2B (ENSG00000272636), SYT15B (ENSG00000277758)

Protein

Protein identifiers

Synaptotagmin-6 — Q5T7P8 (reviewed: Q5T7P8)

Alternative names: Synaptotagmin VI

All UniProt accessions (8): A0A286YEX2, A0A7I2PMW4, Q5T7P8, I6L9C3, V9GY33, V9GYB1, V9GYC4, V9GYY7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in Ca(2+)-dependent exocytosis of secretory vesicles through Ca(2+) and phospholipid binding to the C2 domain or may serve as Ca(2+) sensors in the process of vesicular trafficking and exocytosis. May mediate Ca(2+)-regulation of exocytosis in acrosomal reaction in sperm.

Subunit / interactions. Isoform 1: Homodimer; disulfide-linked via the cysteine motif. Isoform 1: Can also form heterodimers with SYT3, SYT7, SYT9 and SYT10. Isoform 1: Interacts with STX1A, STX1B and STX2; the interaction is Ca(2+)-dependent. Isoform 2: Is not able to form homodimer and heterodimers.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane Membrane Cytoplasm. Cytosol. Cell membrane.

Cofactor. Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 domains.

Domain organisation. The cysteine motif mediates homo- or heterodimer formation via formation of disulfide bonds.

Similarity. Belongs to the synaptotagmin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5T7P8-1	1	yes
Q5T7P8-2	2

RefSeq proteins (7): NP_001240701, NP_001257734, NP_001353152, NP_001353153, NP_001353154, NP_001353155, NP_995320 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR001565	Synaptotagmin	Domain
IPR035892	C2_domain_sf	Homologous_superfamily

Pfam: PF00168

UniProt features (28 total): binding site 16, region of interest 3, topological domain 2, domain 2, chain 1, transmembrane region 1, modified residue 1, splice variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T7P8-F1	73.96	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (16): 260; 260; 266; 318; 318; 319; 320; 320; 320; 323; 326; 326 …

Post-translational modifications (1): 216

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 168 (showing top): GOBP_SINGLE_FERTILIZATION, FREAC2_01, BENPORATH_ES_WITH_H3K27ME3, MYOGENIN_Q6, GCANCTGNY_MYOD_Q6, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_VESICLE_MEDIATED_TRANSPORT, FOXO1_01, GGGTGGRR_PAX4_03, USF_C, CAGCTG_AP4_Q5, EFC_Q6, FOXD3_01, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT

GO Biological Process (4): chemical synaptic transmission (GO:0007268), vesicle-mediated transport (GO:0016192), regulation of calcium ion-dependent exocytosis (GO:0017158), acrosomal vesicle exocytosis (GO:0060478)

GO Molecular Function (7): SNARE binding (GO:0000149), syntaxin binding (GO:0019905), clathrin binding (GO:0030276), protein homodimerization activity (GO:0042803), metal ion binding (GO:0046872), calcium ion sensor activity (GO:0061891), protein binding (GO:0005515)

GO Cellular Component (11): cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasmic side of plasma membrane (GO:0009898), membrane (GO:0016020), synaptic vesicle membrane (GO:0030672), exocytic vesicle (GO:0070382), perinuclear endoplasmic reticulum (GO:0097038), cytoplasm (GO:0005737), transport vesicle membrane (GO:0030658), cytoplasmic vesicle (GO:0031410), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
calcium-ion regulated exocytosis	2
protein binding	2
cytoplasm	2
transport vesicle	2
anterograde trans-synaptic signaling	1
transport	1
cellular process	1
regulation of regulated secretory pathway	1
acrosome reaction	1
SNARE binding	1
identical protein binding	1
protein dimerization activity	1
cation binding	1
calcium ion binding	1
metal ion sensor activity	1
binding	1
membrane	1
cell periphery	1
plasma membrane	1
cytoplasmic side of membrane	1
synaptic vesicle	1
exocytic vesicle membrane	1
secretory vesicle	1
endoplasmic reticulum	1
perinuclear region of cytoplasm	1
intracellular anatomical structure	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

936 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SYT6	EFR3A	Q14156	478
SYT6	RORB	Q92753	471
SYT6	SYNDIG1L	A6NDD5	470
SYT6	CPLX3	Q8WVH0	452
SYT6	PGLYRP4	Q96LB8	432
SYT6	GNG7	O60262	418
SYT6	FARP2	O94887	416
SYT6	CEP41	Q9BYV8	413
SYT6	OR52N1	Q8NH53	411
SYT6	DLGAP3	O95886	409
SYT6	SYNPR	Q8TBG9	406
SYT6	CUX2	O14529	405
SYT6	OR52N5	Q8NH56	405
SYT6	ERC2	O15083	403
SYT6	PRDM8	Q9NQV8	402
SYT6	DRD1	P21728	402

IntAct

10 interactions, top by confidence:

A	B	Type	Score
	SYT6	psi-mi:“MI:0915”(physical association)	0.400
YES1	HSPB1	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
TMPRSS11E	RAB4A	psi-mi:“MI:0914”(association)	0.350
SYT6	SYT10	psi-mi:“MI:0914”(association)	0.350
SYT6	SUPT5H	psi-mi:“MI:0914”(association)	0.350

BioGRID (132): SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), SYT6 (Two-hybrid), ZBTB8A (Two-hybrid), BRCA1 (Two-hybrid), SYT10 (Affinity Capture-MS), SYT3 (Affinity Capture-MS), CETN3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B4J1F4, A0A0G2JXN2, A2AWP8, A2RRH5, C9J798, O43374, O70277, O95294, P04629, P59926, Q0GA42, Q13368, Q14318, Q16512, Q29RM4, Q2HY40, Q2T9P3, Q2TBA3, Q5BIM1, Q5M7W1, Q5R5M3, Q5R811, Q5T7P8, Q5XIS9, Q62746, Q6PFQ7, Q6PFY8, Q7TNM2, Q7TP90, Q7Z4K8, Q8BG60, Q8BHT7, Q8BQC3, Q8C6N3, Q8CIW5, Q8IZ69, Q8NCT1, Q920N2, Q92546, Q925B4

Diamond homologs: A0A075F932, A0FGR8, A4IJ05, K8FE10, O00445, O00750, O08625, O08835, O35681, O43581, P04409, P05128, P05129, P05130, P05696, P10102, P10829, P13677, P17252, P20444, P21521, P21579, P21707, P24505, P24506, P24507, P29101, P34693, P40748, P40749, P41823, P41885, P46096, P46097, P47191, P47708, P47709, P47861, P48018, P50232

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PRKCB	“up-regulates activity”		phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1450 predictions. Top by Δscore:

Variant	Effect	Δscore
1:114099089:CCTA:C	donor_gain	1.0000
1:114099090:CTACC:C	donor_loss	1.0000
1:114099092:A:AC	donor_gain	1.0000
1:114099093:C:CC	donor_gain	1.0000
1:114099093:CCGAT:C	donor_gain	1.0000
1:114099261:GGGAT:G	acceptor_gain	1.0000
1:114099263:GATC:G	acceptor_loss	1.0000
1:114099264:ATCTG:A	acceptor_loss	1.0000
1:114099266:C:CC	acceptor_gain	1.0000
1:114099266:C:T	acceptor_loss	1.0000
1:114099268:G:C	acceptor_gain	1.0000
1:114099271:CCAA:C	acceptor_gain	1.0000
1:114099272:C:T	acceptor_gain	1.0000
1:114099272:CAA:C	acceptor_gain	1.0000
1:114099273:A:T	acceptor_gain	1.0000
1:114099274:A:AC	acceptor_gain	1.0000
1:114099274:A:C	acceptor_gain	1.0000
1:114099281:C:CT	acceptor_gain	1.0000
1:114099282:A:T	acceptor_gain	1.0000
1:114137493:A:AC	donor_gain	1.0000
1:114137494:C:CC	donor_gain	1.0000
1:114137494:CA:C	donor_gain	1.0000
1:114137494:CACT:C	donor_gain	1.0000
1:114137494:CACTT:C	donor_gain	1.0000
1:114139611:TCACC:T	donor_loss	1.0000
1:114139612:CACC:C	donor_loss	1.0000
1:114139613:ACCTG:A	donor_loss	1.0000
1:114099263:GAT:G	acceptor_gain	0.9900
1:114099272:C:CT	acceptor_loss	0.9900
1:114103596:GGTAC:G	donor_loss	0.9900

AlphaMissense

3358 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:114097765:A:G	W493R	1.000
1:114097765:A:T	W493R	1.000
1:114097807:A:G	W479R	1.000
1:114097807:A:T	W479R	1.000
1:114097854:C:T	G463E	1.000
1:114097855:C:G	G463R	1.000
1:114097855:C:T	G463R	1.000
1:114099097:T:A	D454V	1.000
1:114099097:T:G	D454A	1.000
1:114099102:G:C	D452E	1.000
1:114099102:G:T	D452E	1.000
1:114099103:T:A	D452V	1.000
1:114099103:T:C	D452G	1.000
1:114099103:T:G	D452A	1.000
1:114099104:C:G	D452H	1.000
1:114099109:A:T	V450D	1.000
1:114099121:A:G	L446P	1.000
1:114099156:A:C	F434L	1.000
1:114099156:A:T	F434L	1.000
1:114099158:A:G	F434L	1.000
1:114099181:G:T	P426H	1.000
1:114099208:G:A	T417I	1.000
1:114099208:G:C	T417R	1.000
1:114099208:G:T	T417K	1.000
1:114099252:T:A	K402N	1.000
1:114099252:T:G	K402N	1.000
1:114099260:A:C	Y400D	1.000
1:114099262:G:C	P399R	1.000
1:114099262:G:T	P399H	1.000
1:114103617:G:C	D392E	1.000

dbSNP variants (sampled 300 via entrez): RS1000003805 (1:114121160 T>C), RS1000038834 (1:114102641 T>C), RS1000044549 (1:114107137 G>C), RS1000077167 (1:114144034 A>T), RS1000180327 (1:114106983 ACT>A), RS1000206540 (1:114149826 C>T), RS1000248024 (1:114112345 T>C), RS1000274742 (1:114115713 C>A,G), RS1000329555 (1:114110646 G>C), RS1000368965 (1:114155825 T>C), RS1000398474 (1:114147136 G>A), RS1000415971 (1:114117482 G>T), RS1000448750 (1:114110455 G>T), RS1000526780 (1:114148808 A>T), RS1000531659 (1:114125512 A>G)

Disease associations

OMIM: gene MIM:607718 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001762_512	Obesity-related traits	2.000000e-06
GCST001762_676	Obesity-related traits	2.000000e-06
GCST001816_1	Breast cancer (prognosis)	8.000000e-06
GCST010002_392	Refractive error	8.000000e-20

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004578	homocysteine measurement
EFO:0005134	amino acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	3
Benzo(a)pyrene	affects methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
arsenite	increases methylation	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1
Rotenone	decreases expression	1
Thimerosal	decreases expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery